Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

• Author: Jiang, Qian ; Li, Zongru ; Qin, Yazhen ; Li, Weiming ; Xu, Na ; Liu, Bingcheng ; Zhang, Yanli ; Meng, Li ; Zhu, Huanling ; Du, Xin ; Chen, Suning ; Liang, Yang ; Hu, Yu ; Liu, Xiaoli ; Song, Yongping ; Men, Lichuang ; Chen, Zi ; Niu, Qian ; Wang, Hengbang ; Lu, Ming ; Yang, Dajun ; Zhai, Yifan ; Huang, Xiaojun
• Subjects: Product development ; Tyrosine
• Is Part Of: Journal of hematology and oncology, 2023-02, Vol.16 (1), p.13-13, Article 13
• Publisher: England: BioMed Central Ltd
  
• Language: English
  
• Identifier: ISSN: 1756-8722
  EISSN: 1756-8722
  DOI: 10.1186/s13045-023-01414-8
  PMID: 36803531
  
• Source: GFMER Free Medical Journals
  PubMed Central
  ROAD: Directory of Open Access Scholarly Resources
  ProQuest Central
  DOAJ Directory of Open Access Journals
  Springer Nature OA Free Journals